Akums Drugs & Pharmaceuticals announced a total dividend of Rs 3 per share. However, consolidated net profit (PAT) declined in FY 2025-26 compared to the previous year, attributed to rising raw material and manpower costs.

Akums Drugs & Pharmaceuticals Ltd. FY2026 Update

Consolidated Revenue: Rs 4,487.74 Cr | Consolidated PAT: Rs 256.40 Cr

Reader Takeaway: Revenue and EBITDA grew, but PAT fell due to higher costs; dividend payout offers a return.

What just happened

Akums Drugs and Pharmaceuticals Ltd. has announced its financial results for the fiscal year 2025-26. The company's board has recommended a total dividend of Rs 3.00 per equity share (Re 1 final + Rs 2 special), with a record date set for July 3, 2026. The Annual General Meeting (AGM) to approve these and other resolutions is scheduled for July 10, 2026.

Why this matters

The dividend payout offers a direct return to shareholders. However, investors need to consider the decline in consolidated Profit After Tax (PAT) to Rs 256.40 crore in FY 2025-26, down from Rs 343.78 crore in FY 2024-25. This drop, despite revenue and EBITDA growth, is linked to increased operational costs, signaling potential margin pressure.

The backstory

For the fiscal year 2025-26, Akums Drugs reported consolidated revenue of Rs 4,487.74 crore, an increase from Rs 4,170.28 crore in the prior year. Consolidated EBITDA also saw a rise to Rs 522.03 crore from Rs 460.61 crore. Standalone revenue grew to Rs 1,461.70 crore from Rs 1,435.98 crore.

What changes now

The board has proposed a special resolution to cap the annual remuneration for Managing Directors Mr. Sanjeev Jain and Mr. Sandeep Jain at Rs 12 crore each. This cap applies to their fixed and variable pay for their remaining tenure. In FY 2025-26, their actual remuneration was Rs 8.66 crore and Rs 8.62 crore respectively.

Risks to watch

Management attributes the lower PAT to increased raw material and manpower costs, exacerbated by geopolitical events. The company's ability to normalize these costs and improve profitability in the coming fiscal year is a key factor for future performance.

Peer comparison

Management stated that the proposed remuneration for MDs is benchmarked against industry peers and represents approximately 4.60% of the consolidated operating EBITDA for FY 2025-26.

Context metrics (time-bound)

• Dividend: Rs 3.00 per share (Record Date: July 3, 2026).
• Consolidated Revenue FY26: Rs 4,487.74 Cr (vs Rs 4,170.28 Cr FY25).
• Consolidated EBITDA FY26: Rs 522.03 Cr (vs Rs 460.61 Cr FY25).
• Consolidated PAT FY26: Rs 256.40 Cr (vs Rs 343.78 Cr FY25).
• MD Remuneration Cap: Rs 12 Crore per annum each.

What to track next

Investors will be closely watching the company's efforts to manage cost pressures and indications of margin recovery in future financial updates. The outcome of the AGM resolutions regarding director re-appointment and auditor remuneration will also be important.